Showing results (481-490 of 1,835) with videos related to

Sort By:
Pageof 184
ESMO Open|September 18, 2022
Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatmentE Aamdal, E Skovlund, K D Jacobsen, et al.
ESMO Open|September 9, 2022
Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumorsH Park, G I Shapiro, X Gao, et al.
ESMO Open|December 17, 2021
Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II studyJ A Ledermann, B Zurawski, F Raspagliesi, et al.
ESMO Open|December 20, 2021
Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global surveyT Cufer, M Kosty, P Osterlund, et al.
ESMO Open|January 20, 2022
11 ESMO 2021 breakthroughs: practicing oncologist's perceptions on data presentationH K van Halteren, A Tan, B Pellegrino, et al.
ESMO Open|December 25, 2021
Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkersM Palmeri, J Mehnert, A W Silk, et al.
ESMO Open|December 25, 2021
Molecular characterization and clinical outcomes in EGFR-mutant de novo MET-overexpressed advanced non-small-cell lung cancerJ Mi, Z Huang, R Zhang, et al.
ESMO Open|March 12, 2021
Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup studyM Guida, S Strippoli, M Maule, et al.
ESMO Open|March 13, 2021
Clinical prognostic factors in advanced epithelioid haemangioendothelioma: a retrospective case series analysis within the Italian Rare Cancers NetworkA M Frezza, A Napolitano, R Miceli, et al.
ESMO Open|October 20, 2022
The meaning of screening: detection of brain metastasis in the adjuvant setting for stage III melanomaS H A E Derks, K de Joode, E E A P Mulder, et al.
Pageof 184